ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
Cara Therapeutics Initiates Second Pruritus Phase 2 Trial of Peptelligence? americanpharmaceuticalreview
June 28, 2019Enteris BioPharma congratulates Cara Therapeutics on the successful initiation of its Phase 2 clinical trial of Oral KORSUVA? (CR845/difelikefalin) for the treatment of pruritus in patients with hepatic impairment due to primary biliary cholangitis (PBC).
Pharma Sources Insight January 2025
